SeaStar Medical Reports Update on Nasdaq Listing Status

Core Viewpoint - SeaStar Medical Holding Corporation has undertaken several transactions to ensure compliance with Nasdaq's continued listing standards after receiving a notification regarding non-compliance with market value requirements [2][3]. Group 1: Compliance and Financial Transactions - SeaStar Medical received a notification from Nasdaq on June 24, 2024, indicating non-compliance with the minimum market value requirement of $35 million [2]. - The Nasdaq Hearings Panel granted an extension until June 22, 2025, for the company to demonstrate compliance with an alternative requirement of $2.5 million in stockholders' equity [2]. - The company completed a $4.0 million public offering of common stock and warrants on June 23, 2025, and entered into a purchase agreement with Lincoln Park Capital for up to $15.0 million in common stock purchases over three years [6]. Group 2: Business Operations and Product Development - SeaStar Medical increased its customer count to six for its FDA-approved product, QUELIMMUNE, which reduces pediatric mortality by approximately 50% in patients with multiple organ failure [3][4]. - The company initiated a cost-cutting program in May 2025, expected to reduce operating expenses for the remainder of the fiscal year without materially impacting operations [3]. - Approximately $1.2 million in employee compensation and director fee liabilities were extinguished as certain employees and directors waived their rights to unpaid bonuses and fees [3]. Group 3: Product Overview and Clinical Trials - QUELIMMUNE therapy is designed for children with acute kidney injury (AKI) and sepsis, approved under a Humanitarian Device Exemption in February 2024, and launched commercially in July 2024 [4][10]. - The NEUTRALIZE-AKI pivotal trial is evaluating the safety and efficacy of the Selective Cytopheretic Device (SCD) therapy in 200 adults with AKI, focusing on 90-day mortality and dialysis dependency as primary endpoints [7]. - The SCD therapy aims to neutralize over-active immune cells and mitigate hyperinflammation, with potential applications in various acute and chronic kidney and cardiovascular diseases [9][10].